4D Molecular Therapeutics, Inc. reported $120K of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $120K (to Q3 2025). Net income: −$179M, trailing twelve months to Q2 2026. Free cash flow: −$110M, trailing twelve months to Q4 2025. Operating margin: −1614766%, trailing twelve months to Q3 2025.

FDMT4D Molecular Therapeutics, Inc.

Healthcare

$12.69+53% 1Y

$12.69

$7.1952 weeks$16.74

FDMT as reported

4D Molecular Therapeutics, Inc. reported $120K of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$120K

Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied

Net income: −$179M
Net income · −8.7% year on year · trailing twelve months to Q2 2026
Free cash flow: −$110M
Free cash flow · trailing twelve months to Q4 2025
Operating margin: −1614766%
Operating margin · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for FDMT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$120K	n/a	Q3 2025
Net income	−$179M	−8.7%	Q2 2026
EPS	−$2.63	−25%	Q2 2026
Operating margin	−1614766%	n/a	Q3 2025
Net margin	−1434335%	n/a	Q3 2025
ROE	−41%	n/a	Q2 2026
ROA	−35%	n/a	Q2 2026
Free cash flow	−$110M	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.